On Tuesday, Mankind Pharma will begin its first public offering. The deadline for submission of bids and offers is set for Thursday, April 27, 2023.
A wide variety of acute and chronic pharmaceutical formulations, as well as a number of consumer healthcare items, are developed and produced by Mankind Pharma.
Data on subscriptions for the Mankind Pharma IPO as of April 25, 5:00 p.m.
QIB – 0.08x,
NII is 0.33x, NII 10L+ is 0.37x, and NII 2L–10L is 0.25x, respectively.
Wholesale: 0.10x
Overall, 0.14x
Mankind Pharma’s IPO Schedule
On April 25, the offer was made public, and it would close on April 27, 2023. On April 24, the day before the launch of the IPO, the business will open its anchor book, a component of the QIB section.
Mankind Pharmaceuticals IPO Cost
Mankind Pharma’s IPO pricing range has been set by the business at Rs. 1026 to Rs. 1080 per equity share.
Size of the Mankind Pharma IPO Offer
There is no new issue component to the debut public offering; instead, promoters and investors are merely offering to sell more than 4 crore equity shares.
At the lower price range, the corporation would raise $4,110.03, and at the higher price band, $4,326.35 crore.
Over 1 crore shares will be sold via an offer for sale by the three promoters Ramesh Juneja, Rajeev Juneja, and Sheetal Arora, with the remaining shares in the OFS being offered by the following investors: Cairnhill CIPEF, Cairnhill CGPE, Beige, and Link Investment Trust.
Mankind Pharmaceutical IPO Goals
The major goals of the offer would be to complete the selling shareholders’ offer for sale and reap the rewards of listing the equity shares on public markets.
The corporation won’t get any money from the offer; all proceeds from public offerings will go to selling shareholders.
Financial Mankind Pharma IPO
For the nine months that ended in December of FY23, the pharmaceutical company, which has a market capitalization of Rs 43,264 crore, reported a consolidated profit of Rs 996.4 crore, a 20 percent decrease from the same period the previous year due to lower other income, higher employee costs, and subpar operating results.
While operating results have seen a nearly 13 percent YoY decline in EBITDA (earnings before interest, tax, depreciation, and amortization), at Rs 1,484 crore, with margin falling 598 basis points compared to the same period last fiscal, overall revenue for 9MFY23 increased by 10.6 percent year over year to Rs 6,697 crore.
Today’s Mankind Pharma IPO GMP
According to sources, Mankind Pharma’s most recent GMP indicates a premium of Rs 90, indicating that the company would have a respectable start when it is listed on the stock market.
On Day 2, should you subscribe to Mankind Pharma’s IPO?
Given the company’s excellent brand image and potential for development despite not quite low values, the majority of analysts are optimistic about it.
The issue gets a “subscribe” rating from ICICI Direct because it believes Makind would profit from its position as a leader in domestic branded formulations with a focus on cost-effective product offerings.
According to the brokerage, the subscribe rating is the result of opportunities from its more recent acquired items and its goal to backward-integrate its power brands.
“After the IPO, the promoter will still own 78% of the business, and current PE investors would own the remaining 12%. The stock is well-positioned from the standpoint of float thanks to its substantial promoter ownership. According to Ashika Research, the Mankind Pharma IPO offers investors a compelling opportunity with a favorable risk-reward perspective.
